Carregant...
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
BACKGROUND: The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis. The present study aimed to examine the chemotherapeutic effects of a flavonoid proanthocyanidin B2 (PB2) on HCC. METHO...
Guardat en:
| Publicat a: | J Exp Clin Cancer Res |
|---|---|
| Autors principals: | , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6525465/ https://ncbi.nlm.nih.gov/pubmed/31101057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1194-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|